Q2 2026 13F · SEC CIK 1230765
Rice Hall James & Associates, LLC
Asset managerFiled 2026-08-07 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $2.1B
- Reported positions
- 240
- Top holdings a year, 3 yrs
- +20.8%
- Assets under management
- $1.7B
Rice Hall James & Associates, LLC is an asset manager that reported 240 positions worth $2.1B in its Q2 2026 13F, filed 2026-08-07. Its largest holdings were Ligand Pharmaceuticals Inc (LGND, 4.2%), ACI Worldwide Inc (ACIW, 2.5%), Arlo Technologies Inc Com (ARLO, 2.4%). A portfolio copying its top holdings returned 20.8% a year over the last 3 years, against 20.4% for the S&P 500.
Rice Hall James & Associates, LLC holdings largest 50 of 240 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
What Rice Hall James & Associates, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
Q1 2026's filing was too long to tell new positions apart.
Added to
- UPWK Upwork Inc+112.3% shares
- LCII Lci Inds+35.4% shares
- PBH Prestige Consumer Health+32.2% shares
- VRDN Viridian Therapeutics Inc+30.9% shares
- WIX Wix Com Ltd+28.9% shares
- MMS Maximus Inc+25.1% shares
- G Genpact Limited+18.4% shares
- VREX Varex Imaging Corp+13.4% shares
Reduced
- MIRM Mirum Pharmaceuticals Inc-24.7% shares
- FN Fabrinet-17.2% shares
- YOU Clear Secure Inc-16.0% shares
- ITRN Ituran Location and Control-10.6% shares
Left the top 50
- Ascendis Pharma A/swas 1.9%
- DOX Amdocs Ltdwas 0.9%
- GTLS Chart Inds Incwas 0.8%
- CRAI CRA Intl Incwas 0.7%
- SSTK Shutterstock Incwas 0.7%
Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.
How the holdings did against the S&P 500.
- 1 year
- +9.8% /yr
- S&P 500 +20.1%
- 3 years
- +20.8% /yr
- S&P 500 +20.4%
- 5 years
- +7.7% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $2.1B | 240 |
| Q1 2026 | $1.8B | 243 |
| Q4 2025 | $1.8B | 243 |
| Q3 2025 | $1.8B | 248 |
| Q2 2025 | $1.9B | 247 |
| Q1 2025 | $1.7B | 248 |
| Q4 2024 | $1.8B | 249 |
| Q3 2024 | $1.8B | 250 |
| Q2 2024 | $1.7B | 256 |
| Q1 2024 | $1.8B | 257 |
| Q4 2023 | $1.7B | 260 |
| Q3 2023 | $1.6B | 260 |
Questions about Rice Hall James & Associates, LLC's portfolio
What stocks does Rice Hall James & Associates, LLC own?
Rice Hall James & Associates, LLC's latest 13F, for Q2 2026 and filed Aug 7, 2026, lists 240 positions worth $2.1B. The largest are Ligand Pharmaceuticals Inc (LGND) at 4.2%, ACI Worldwide Inc (ACIW) at 2.5%, Arlo Technologies Inc Com (ARLO) at 2.4%, Fabrinet (FN) at 2.4% and Establishment Labs Hldgs Inc (ESTA) at 2.3%.
What did Rice Hall James & Associates, LLC buy last quarter?
In Q2 2026, Rice Hall James & Associates, LLC added Upwork Inc (UPWK) (+112.3% shares), Lci Inds (LCII) (+35.4% shares) and Prestige Consumer Health (PBH) (+32.2% shares), compared with its Q1 2026 filing.
What did Rice Hall James & Associates, LLC sell last quarter?
In Q2 2026, Rice Hall James & Associates, LLC cut from its top 50 Ascendis Pharma A/s, cut from its top 50 Amdocs Ltd (DOX), cut from its top 50 Chart Inds Inc (GTLS), cut from its top 50 CRA Intl Inc (CRAI), cut from its top 50 Shutterstock Inc (SSTK), Mirum Pharmaceuticals Inc (MIRM) (-24.7% shares), Fabrinet (FN) (-17.2% shares) and Clear Secure Inc (YOU) (-16.0% shares), compared with its Q1 2026 filing.
How has Rice Hall James & Associates, LLC's portfolio performed?
A portfolio copying Rice Hall James & Associates, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +20.8% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +9.8% against +20.1%. Over 5 years: +7.7% a year against +11.6%.
When is Rice Hall James & Associates, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Rice Hall James & Associates, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Rice Hall James & Associates, LLC manage?
Rice Hall James & Associates, LLC reported $1.7B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $2.1B.